title: Expression of monocyte chemotactic protein-3 in human monocytes exposed to the mycobacterial cell wall component lipoarabinomannan.
abstract: Monocyte chemotactic protein-3 (MCP-3) is a C-C chemokine which interacts with the CCR1, CCR2 (MCP-1) and CCR3 receptors and has a distinct spectrum of action. The present study was designed to assess whether mycobacterial components were able to induce expression and production of MCP-3 in human monocytes. Mycobacterial lipoarabinomannan (LAM) induced expression of MCP-3 mRNA in human peripheral blood mononuclear cells. The non-mannose-capped version of lipoarabinomannan (AraLAM) was considerably more potent than the mannose-capped version ManLAM or the simpler version phosphatidylinositol mannoside (PLM). Among mononuclear cells, monocytes were responsible for LAM-induced MCP-3 mRNA expression. Whole mycobacteria (Mycobacterium bovis BCG) strongly induced MCP-3 expression. Pretreatment with actinomycin D abolished LAM-induced MCP-3 expression, whereas cycloheximide only partially reduced the expression. LAM-induced MCP-3 expression was associated with the production of immunoreactive PTX3. Interleukin 10 (IL-10) and IL-13 inhibited the induction of MCP-3 by LAM. Thus mycobacterial cell wall components induced expression of MCP-3 in human monocytes. MCP-3, a chemokine active on mononuclear phagocytes, NK cells, T cells and dendritic cells, may be relevant to the induction and expression of immunity against mycobacteria.
authors.affiliation: Istituto di Ricerche Farmacologiche "Mario Negri", via Eritrea 62, Milan, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Vouret-Craviari
authors.forename: S
authors.initials: S
authors.lastname: Cenzuales
authors.forename: G
authors.initials: G
authors.lastname: Poli
authors.forename: A
authors.initials: A
authors.lastname: Mantovani
mesh_terms: D002097:C-Reactive Protein / Q000096:biosynthesis; D002478:Cells, Cultured; D054410:Chemokine CCL7; D003513:Cycloheximide / Q000494:pharmacology; D016207:Cytokines; D003609:Dactinomycin / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D016753:Interleukin-10 / Q000494:pharmacology; D018793:Interleukin-13 / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D018945:Monocyte Chemoattractant Proteins / Q000096:biosynthesis*; D009000:Monocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D009163:Mycobacterium bovis; D010716:Phosphatidylinositols / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D000683:Serum Amyloid P-Component / Q000096:biosynthesis; D014158:Transcription, Genetic / Q000187:drug effects*; D000099153:Pentraxins
chemical_list: D002097:C-Reactive Protein; D054410:Chemokine CCL7; D003513:Cycloheximide; D016207:Cytokines; D003609:Dactinomycin; D016753:Interleukin-10; D018793:Interleukin-13; D008070:Lipopolysaccharides; D018945:Monocyte Chemoattractant Proteins; D010716:Phosphatidylinositols; D012333:RNA, Messenger; D000683:Serum Amyloid P-Component; D000099153:Pentraxins; C515450:CCL7 protein, human; C050016:lipoarabinomannan; C034154:phosphatidylinositol mannoside